Abstracts tagged "SLE and treatment"

Abstract Number: 29 • 2017 ACR/ARHP Annual Meeting
BTK Inhibition Ameliorates Lupus-Associated Neuropsychiatric and Skin Disease
Samantha Chalmers¹, Jing Wen¹, Jessica Doerner¹, Ariel Stock², Carla Cuda³, Hadijat Makinde³, Harris Perlman⁴, Todd Bosanac⁵, Deborah Webb⁵, Gerald Nabozny⁶, Elliott Klein⁵, Jay S. Fine⁵, Meera Ramanujam⁵ and Chaim Putterman⁷, ¹Albert Einstein College of Medicine, Bronx, NY, ²Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, ³Northwestern University, Chicago, IL, ⁴Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Northwestern University Feinberg School of Medicine,, Chicago, IL, ⁵Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ⁶[email protected], Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ⁷Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY
Background/Purpose: The importance of macrophages in the pathogenesis of cutaneous and neuropsychiatric systemic lupus erythematosus (SLE) is well established. Additionally, autoantibodies produced by autoreactive…
Abstract Number: 1812 • 2015 ACR/ARHP Annual Meeting
The First Randomized Control Trial to Evaluate the Effectiveness of Bortezomib for Refractory Systemic Lupus Erythematosus
Tomonori Ishii¹, Yoshiya Tanaka², Atsushi Kawakami³, Kazuyoshi Saito², Kunihiro Ichinose⁴, Yuko Shirota⁵, Hiroshi Fujii⁵, Yoko Fujita⁶, Yukiko Kamogawa⁵, Tomoaki Machiyama⁵, Kanae Akita⁵ and Hideo Harigae⁵, ¹Department of Clinical Trial Implementation, Tohoku University Hospital, Clinical Research, Innovation and Education Center, Sendai, Japan, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ³Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, ⁴Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁵Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, ⁶Department of Hematolgy and Rheumatolgy, Tohoku University Graduate School of Medicine, Sendai, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is a disease characterized by production and deposition of anti-dsDNA antibody. In recent years, treatment methods targeting antibody-producing B cell…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].